Open company graph database — free web & API
Login

Bright Path Bio Inc.

ブライトパス・バイオ株式会社BrightPath Biotherapeutics Co., Ltd.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
24
Related companies
1
§01

Basic information

BASIC
Head office
7F, Koji-machi Central Building, 2-2-4 Koji-machi, Chiyoda-ku, Tokyo, Japan
Chief executive
Kenichi Nagai
Capital
1,199,000,000 JPY (11 100 millionJPY)
Employees (non-consolidated)
24 people
Employees (consolidated)
24 people
Start date
2003-05-08
End date
§02

Websites

1 DOMAINS
§03

Business

0
§04

Related companies

1 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Mitsubishi UFJ Trust and Banking Corporation
Bank
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

17 EVENTS

Established our company at 67 Asahimachi, Kurume City, Fukuoka Prefecture (Capital: 10,000 thousand yen)Sources

Initiated Phase I clinical trial for castration-resistant prostate cancer with ITK-1Sources

Concluded an exclusive license agreement with Fujifilm Corporation regarding ITK-1Sources

Initiated Phase III clinical trial for castration-resistant prostate cancer with ITK-1Sources

Results of interim analysis of Phase III clinical trial for castration-resistant prostate cancer with ITK-1 indicate a high likelihood of achieving the main evaluation items in the final analysis, and the Effectiveness and Safety Evaluation Committee recommends continuing the trial as planned.Sources

Started Phase I clinical trial in the US for melanoma (malignant melanoma) with GRN-1201Sources

Listed on the Tokyo Stock Exchange Mothers MarketSources

Established Kawasaki Drug Discovery Institute in the Tonemachi district, Kawasaki City, Kanagawa PrefectureSources

Initiated Phase II clinical trial in the US for non-small cell lung cancer using GRN-1201 in combination with immune checkpoint inhibitorsSources

Changed company name to BrightPath Biotherapeutics Co., Ltd.Sources

Participated in the iPS cell-derived regenerative NKT cell therapy development project by RIKEN, a National Research and Development AgencySources

Conducted key opening for Phase III clinical trial of ITK-1 in patients with castration-resistant prostate cancerSources

Discontinued development of ITK-1Sources

Relocated head office to 3-25-22 Tonemachi, Kawasaki-ku, Kawasaki City, Kanagawa PrefectureSources

Initiated physician-led clinical trial of iPS-NKT cell therapySources

Initiated physician-led clinical trial of HER2 CAR-T cell therapy (BP2301)Sources

Announced early termination of Phase II clinical trial of GRN-1201 in the USSources

§07

News

82 ARTICLES

Publication of a paper on iPS cell-derived CAR-NKT cellsSources

A co-authored paper with the RIKEN and Chiba University research groups on iPS cell-derived CAR-NKT cells targeting solid tumors, which Bright Path Bio is researching, was published in the "Journal for ImmunoTherapy of Cancer" on October 20, 2026. The paper discusses how HER2-targeted CAR-NKT cells exhibit multifaceted immune regulatory functions beyond direct tumor damage.

Publication of Paper on iPSC-derived CAR-NKT CellsSources

A co-authored paper with the Institute of Physical and Chemical Research and Chiba University, concerning iPSC-derived CAR-NKT cells targeting solid tumors, was published in the journal 'Journal for ImmunoTherapy of Cancer' on October 20, 2026. The paper reports that CAR-NKT cells targeting HER2 not only directly damage tumors but also exhibit multifaceted immune regulatory functions.

Announcement of Completion of Payment for the 21st Issue of Stock Options Allocated to Third PartiesSources

Bright Path Bio Inc. reported that it has completed the payment for the 21st issuance of stock options (with exercise price adjustment clause) allocated to third parties. The number of shares issued was 345,000, with a total amount of 2,415,000 yen, and the payment of 1,952,915,000 yen was completed. The potential number of shares is 34,500,000, with an initial exercise price of 57 yen, which will be adjusted according to 97% of the closing price of the exchange.

Announcement of Completion of Payment for the 21st Issue of Stock Rights with Exercise Price Adjustment ClauseSources

On October 5, 2026, we issued the 21st stock rights (with exercise price adjustment clause) through a third‑party allocation, and the payment of 2,415,000 yen was completed. The number of shares issued was 345,000, and the potential number of shares is 34,500,000 (100 shares per right). The exercise price was initially 57 yen, and from the trading day following the allocation date, it will be adjusted based on 97% of the closing price of the exchange.

Nikkei Bio Online Covers BrightPath Bio’s U.S. Clinical Trial StartSources

On September 28, 2026, Nikkei Bio Online published an article about the start of a U.S. clinical trial of BrightPath Bio’s allogeneic iPS cell-derived CAR-NKT therapy.

Nikkei Bio Online Covers BrightPath Bio’s U.S. Clinical Trial StartSources

On September 28, 2026, Nikkei Bio Online published an article about the start of a U.S. clinical trial of BrightPath Bio’s allogeneic iPS cell-derived CAR-NKT therapy.

Notice of BrightPath Publication (September 25, 2026)Sources

BrightPath Bio Inc. is participating in the annual scientific conference of the International Myeloma Society (IMS2026).

Notice of BrightPath Newsletter Publication (September 25, 2026)Sources

BrightPath Bio Inc. is participating in the annual scientific conference of the International Myeloma Society (IMS2026). The news has been published in the BrightPath Newsletter.

Research on iPS Cell-Derived BCMA CAR-NKT Therapy PresentedSources

BrightPath Biotherapeutics presented preclinical research results on its iPS cell-derived BCMA CAR-NKT cell therapy (BP2202) and the design of its Phase I clinical trial at IMS 2026 on September 23, 2026.

Supplementary Video on 21st Stock Acquisition Rights Offering PublishedSources

BrightPath Biotherapeutics Co., Ltd. posted a supplementary explanatory video on September 24, 2026, concerning its issuance of the 21st stock acquisition rights with an exercise price adjustment clause.

§08

Public records

GOV
National Tax Agency basic information8290001050314
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
ブライトパス・バイオ株式会社
Trade name (kana)
ブライトパスバイオ
Name in English
Corporation type
301
Address
〒210-0821 神奈川県川崎市川崎区殿町3丁目25番22号
Postal code
2100821
Prefecture code
14
City code
131
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2019-07-23
Change date
2019-07-18
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
2937666
METI gBizINFO8290001050314
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
8290001050314
Trade name
ブライトパス・バイオ株式会社
Trade name (kana)
ブライトパスバイオ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
神奈川県川崎市川崎区殿町3丁目25番22号
Postal code
2100821
Prefecture
神奈川県
Prefecture code
14
City or district
川崎市川崎区
City code
131
Street address
殿町3丁目25番22号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長 永井 健一
Capital
2574735000
Employees
23
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2019-07-23
Key information
8290001050314
§09

Sources & updates

SOURCES
↑